Patient Advocacy Organizations

Founded in 2020, the Autistic Psychedelic Community (APC) is a Los Angeles-based peer support and co-learning network focused on the intersection of psychedelics and neurodivergent conditions including autism and ADHD, offering psychedelic integration support, panel discussions with researchers, and academic partnerships. Cited in peer-reviewed research, the APC promotes neurodiversity-affirming approaches to psychedelic practice and safe access.

The European Federation of Neurological Associations (EFNA) is a Brussels-based umbrella organization representing 21 pan-European neurology patient groups, advocating for improved access and resources for people with neurological disorders. EFNA participates as a patient advocacy partner in the PsyPal consortium, the first EU-funded multi-site psilocybin clinical trial (€6.5M) studying psilocybin for psychological distress in palliative care neurological patients.

HYSTELICA is a non-profit researching, advocating, and educating for safe and effective psychedelic use for women, with a focus on ensuring women-specific needs shape the future of psychedelics.

Heal Ukraine Trauma is a U.S.-based non-profit providing evidence-based mental health support to Ukrainian veterans and their families healing from war trauma.

Veteran-serving nonprofit supporting access to psychedelic programs and advocating policy pathways that expand safe treatment options for veterans and their families.

Heroic Hearts UK connects UK military and emergency services veterans with psychedelic therapy retreat centres in countries where those practices are legal.

Irish Doctors for Psychedelic Assisted Therapy is a non-profit improving awareness of psychedelic research among clinicians and policymakers and advocating for state-funded psychedelic research trials.

Long Alliantie Nederland (Lung Alliance Netherlands) is the Dutch national patient alliance representing people with lung diseases including COPD, asthma, and pulmonary fibrosis; as one of 19 consortium partners in the EU Horizon Europe–funded PsyPal trial (€6.5M), the Alliance contributes patient expertise for the COPD arm investigating psilocybin therapy for psychological distress in palliative care.

Psilocybin Access Rights is a volunteer campaign pressing the UK government to reschedule psilocybin and make it accessible for patients and researchers.

Reconnect Foundation is a Swiss non-profit supporting consciousness research, mental health care accessibility, and Indigenous stewardship of ecosystems and biodiversity.

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

The Ukrainian Psychedelic Research Association convenes academics, clinicians, patients, and activists to advance legal therapeutic use and scientific psychedelic research in Ukraine.

Veteran-led nonprofit coalition advocating federal and state policy reform to expand access to psychedelic-assisted therapies and reduce veteran suicide.

Veteran-focused nonprofit advocating expanded access to psychedelic-assisted therapies, especially for PTSD and related conditions, through policy engagement and public education.